

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in this Application.

1. (Currently amended) A ~~composition comprising a~~ phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity and wherein the phenolic antioxidant is in a purified tannin fraction of plant origin.

2. (Currently amended) The ~~composition—complex~~ of claim 1, wherein the hyperglycemia is due to a diabetic condition.

3. – 5. (Canceled).

6. (Currently amended) The ~~composition—complex~~ of claim 1, wherein the chromium content in the complex is 0.01 to 20% of the complex.

7. (Currently amended) The ~~composition—complex~~ of claim 6, wherein the chromium content in the complex is from 0.02 to 10%.

8. (Canceled).

9. (Currently amended) The ~~composition—complex~~ of claim 1, wherein the ~~phenolic antioxidant~~ tannin fraction comprises low molecular weight hydrolyzable tannin having a molecular weight below 2,000.

10. (Currently amended) The ~~composition—complex~~ of claim 9, wherein the phenolic antioxidant is ~~obtained~~ from the genus Phyllanthus, Terminalia, Gardenia, Geranium, Erodium or Tamarix.

11. (Currently amended) The ~~composition—complex~~ of claim 9, wherein the hydrolyzable tannin is ~~obtained~~ from Phyllanthus emblica (syn. Emblica officinalis), Phyllanthus amarus, Phyllanthus flexuosus, other Phyllanthus species, Terminalia bellerica, other Terminalia species, Erodium pelagonium, Geranium thumbergi, Tamarix aphyla or other Tamarix species.

12. (Canceled).

13. (Currently amended) The ~~composition-complex~~ of claim 11, wherein the hydrolyzable tannin is ~~obtained~~ from the *Phyllanthus emblica* fruit.

14. (Currently amended) ~~The composition of claim 1,~~ A phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity and wherein the phenolic antioxidant comprises oxygenated dibenzo- $\alpha$ -pyrone (DBP) or a DBP conjugate and fulvic acid.

15. (Currently amended) The ~~composition-complex~~ of claim 14, wherein the oxygenated dibenzo- $\alpha$ -pyrone (DBP) or DBP conjugate, comprises dimers and oligomers.

16. (Currently amended) The ~~composition-complex~~ of claim 1, ~~wherein the phenolic anti-oxidant is in combination with a second phenolic anti-oxidant-chromium complex, wherein the second phenolic antioxidant is inobtained from Phyllanthus emblica and purified a purified fraction of fulvic acid and phenolic compounds from Shilajit.~~

17-21 (Cancelled)

22. (Currently amended) A formulation of the ~~composition-complex~~ of claim 1, ~~wherein the phenolic antioxidant-chromium complex is combined with~~ and a pharmaceutically or nutritionally acceptable excipient.

23. (Cancelled).

24. (Currently amended) The ~~composition-complex~~ of claim 1, further comprising an additional active ingredient.

25. (Currently amended) The ~~composition-complex~~ of claim 24, wherein the additional active ingredient is an antioxidant, vitamin, carnitine, carnosine, N-acetyl-L-cysteine, biotin, polycosanol, aminoguanidine, fatty acid or plant extract, or mixtures thereof.

26. (Currently amended) The ~~composition-complex~~ of claim 7, wherein the chromium content in the complex is from 1 to 8% of the complex.

27. (Currently amended) The ~~composition-complex~~ of claim ~~19~~1, wherein the molecular weight of the tannin in said tannin fraction is below 1,000.

28. (Withdrawn) A method of treatment for hyperglycemia which comprises administering to a mammal the composition of claim 1.

29. (Withdrawn) The method of claim 28, wherein the hyperglycemia is the result of a diabetic condition.

30. (Previously presented) The formulation of claim 22, wherein the phenolic antioxidant-chromium complex has 10 to 1,000  $\mu\text{g}$  of chromium content.

31-32 (Cancelled)

33. (Currently amended) The ~~composition~~complex of claim ~~31~~14, wherein the ~~phenolic antioxidant is~~ oxygenated dibenzo- $\alpha$ -pyrone (DBP), a-DBP conjugate or fulvic acid ~~of~~ is from purified Shilajit.

34. (Currently amended) The ~~composition~~complex of claim 31, wherein the phenolic antioxidant-chromium complex has 10 to 1,000  $\mu\text{g}$  of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient.

35. (Withdrawn) The method of claim 28, wherein the composition is administered once or twice a day.

36. (Currently amended) The ~~composition~~complex of claim 15, wherein the oxygenated dibenzo- $\alpha$ -pyrone (DBP), DBP conjugate, and fulvic acid are ~~obtained~~ from purified Shilajit.

37. (Cancelled)

38. (New) The complex of claim 14, wherein the phenolic antioxidant-chromium complex has 10 to 1,000  $\mu\text{g}$  of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient.